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Abstract
Introduction
Computer simulation offers the ability to compare diverse inter-
ventions for reducing cardiovascular disease risks in a controlled
and systematic way that cannot be done in the real world.
Methods
We used the Prevention Impacts Simulation Model (PRISM) to
analyze the effect of 50 intervention levers, grouped into 6 (2 x 3)
clusters on the basis of whether they were established or emerging
and whether they acted in the policy domains of care (clinical,
mental health, and behavioral services), air (smoking, secondhand
smoke, and air pollution), or lifestyle (nutrition and physical activ-
ity).  Uncertainty ranges were established through probabilistic
sensitivity analysis.
Results
Results indicate that by 2040, all 6 intervention clusters combined
could result in cumulative reductions of 49% to 54% in the cardi-
ovascular risk-related death rate and of 13% to 21% in risk factor-
attributable costs. A majority of the death reduction would come
from Established interventions, but Emerging interventions would
also contribute strongly. A slim majority of the cost reduction
would come from Emerging interventions.
Conclusion
PRISM allows public health officials to examine the potential in-
fluence of different types of interventions — both established and
emerging — for reducing cardiovascular risks. Our modeling sug-
gests that established interventions could still contribute much to
reducing deaths and costs, especially through greater use of well-
known approaches to preventive and acute clinical care, whereas
emerging interventions have the potential to contribute signific-
antly, especially through certain types of preventive care and im-
proved nutrition.
Introduction
Heart disease and stroke are the first and fourth leading causes of
death in the United States (1) despite being largely preventable.
This situation has raised the call for public health intervention to
improve prevention. Policy makers have a range of choices for
public health intervention to increase prevention through modifi-
able risks, such as smoking, obesity, stress, air pollution, poor diet,
and physical inactivity. The importance of intervening to limit
these risks is described in A Public Health Action Plan to Prevent
Heart  Disease  and  Stroke  (2)  and  highlighted  by  the  Million
Hearts initiative (http://millionhearts.hhs.gov/index.html).
Risk factors can be addressed by implementing established inter-
ventions with a scientific evidence base and emerging interven-
tions with a growing evidence base. To classify interventions as
either emerging or established, we conducted a review of guid-
ance from the Guide to Community Preventive Services (3), Co-
chrane Reviews (4), Health Evidence Reviews (5), US Preventive
Services Task Force (6), National Institutes of Health (7), Americ-
an Heart Association (8), American College of Physicians (9), US
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Department of Agriculture (10), Centers for Disease Control and
Prevention (11), American Psychiatric Association (12), Americ-
an Diabetes Association (13), and American Academy of Sleep
Medicine (14). If more than 50% of the published guidance docu-
ments relating to an intervention from these sources found suffi-
cient evidence to recommend it, we classified the intervention as
established. If less than 50% of the published guidance documents
recommended the intervention or if there was no guidance related
to the intervention, we classified it as emerging.
Computer simulation permits comparison of diverse interventions
in a controlled and systematic way that cannot be done in the real
world. Simulating various interventions individually and in com-
bination and testing across their ranges of uncertainty can help
policy makers evaluate how to balance investments in established
and emerging interventions. In this analysis, we used the Preven-
tion Impacts Simulation Model (PRISM) to compare established
and emerging prevention interventions across the 3 domains of
care, air, and lifestyle, in terms of their potential for reducing the
adverse  consequences  of  cardiovascular  disease  (CVD)  risk
factors in the US population through the year 2040. This analysis
can help inform the policy conversation about what kinds of pre-
vention and care-based interventions are most useful for address-
ing CVD (2,15–17).
Methods
PRISM and its intervention levers
PRISM is a nationally representative computer model that simu-
lates the effects of diverse clinical and population-level interven-
tions aimed at reducing risks for CVD events (ie, acute events
coded as coronary heart disease, stroke, heart failure, or peripher-
al artery disease) and for other chronic conditions and diseases
(eg, hypertension, diabetes, renal disease, obstructive pulmonary
disease, certain cancers) (15,18,19). It is a compartmental system
dynamics model and, like other such models, depicts processes of
multiple and nonlinear influence, accumulation, delay, and feed-
back that result in movements among healthy and ill population
subgroups (20–22). The conceptual and numerical assumptions of
PRISM are drawn from scientific literature, national survey data,
and subject matter expertise. PRISM provides a user-friendly in-
terface and in seconds produces 50 years of simulated output, from
1990 through 2040, answering “what if” questions posed in inter-
active workshops and study sessions. The model has been calib-
rated  to  represent  the  United  States  and  some  local  areas
(18,23,24).
In PRISM, the population is segmented by 6 childhood and adult
age categories, by sex, and by CVD event status (not-yet or non-
CVD,  and  already-had  or  post-CVD).  The  model  simulates
changes in the population through birth, death, migration, aging,
and movement from non-CVD to post-CVD status. It also depicts
flows into and out of 3 blood pressure categories (normal, border-
line,  high),  3 blood cholesterol categories (normal,  borderline,
high), 3 blood glucose categories (normal, prediabetic, diabetic), 4
smoking categories (never, current, recent ex-smoker, long-term
ex-smoker), and 2 body mass index categories (non-obese, obese).
PRISM also includes risk factors of poor nutrition (ie, inadequate
consumption of fruits and vegetables and excess consumption of
junk food, sodium, or trans fats), inactivity, psychological distress,
secondhand smoke, periodontal disease, sleep apnea, small partic-
ulate air pollution, and inadequate use of aspirin for primary pre-
vention. Co-occurrence of these risk factors in individuals is not
modeled explicitly (PRISM is a compartmental model of subpopu-
lations rather than separate individuals), but interactions among
the risk factors are represented algebraically in equations for cardi-
ovascular events and deaths and also in equations describing how
the prevalence of one risk factor (eg, smoking) may affect another
(eg, diabetes). The model simulates changes by quarter-year incre-
ments in more than 4,000 variables, including changes in popula-
tion mix, risk factor prevalence, and risk factor–related morbidity,
mortality, and costs (19).
The current version of PRISM, version 3p, includes 50 interven-
tion levers that may prevent or mitigate the cardiovascular risks
described above. All interventions in the model are based on peer-
reviewed literature and discussions with experts working in the
field who helped to specify and quantify their potential effects
(19).
Testing 6 intervention clusters
We grouped PRISM’s 50 intervention levers into established and
emerging interventions that we crossed with policy categories of
care  (clinical,  behavioral,  and  mental  health  services),  air
(smoking, secondhand smoke, and air pollution), and lifestyle (nu-
trition and physical activity), resulting in 6 clusters (Table 1). For
each intervention, the table gives several pieces of information: es-
timated size of the target population in 2010, the existing recipient
population in 2010 (for care interventions), the unit cost per recipi-
ent per year (for care interventions), the initial (pre-2012) lever
setting for the intervention, and the best plausible (full extent)
lever setting (19).
Within the care policy domain, the established interventions in-
clude the use of quality preventive care for diagnosis and basic
control (that is, according to current standards) of high blood pres-
sure, high cholesterol, and diabetes; quality acute and rehabilitat-
ive care after cardiovascular events; quality care for post-CVD pa-
tients to prevent recurrent events; behavioral services for smoking
PREVENTING CHRONIC DISEASE VOLUME 11, E195
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY   NOVEMBER 2014
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
2       Centers for Disease Control and Prevention  •  www.cdc.gov/pcd/issues/2014/14_0130.htm
cessation and weight loss for the obese; mental health services to
address psychological distress and depression; diagnosis of sleep
apnea and its effective treatment through the use of continuous
positive airway pressure (CPAP) devices; prevention of periodont-
al disease through regular dental care; and the use of aspirin for
primary prevention among middle-aged and older people (men
aged 45 to 79, women aged 55 to 79) who have not had a cardi-
ovascular event. Emerging care interventions include tighter con-
trol (that is, based on lower thresholds than current standards) of
high blood pressure, high cholesterol, and diabetes and the control
of borderline hypertension, borderline cholesterol,  and predia-
betes.
Within the air domain, the established interventions include sever-
al policies for tobacco: taxation, counter-marketing, and prohibi-
tions on workplace smoking. Emerging interventions in the air do-
main are tobacco marketing restrictions and the reduction of small
particulate (PM 2.5, also known as soot) air pollution. Although
the sources of PM 2.5 are well understood and reductions of 50%
or more were achieved from 1990 to 2010, no consensus exists on
how to accomplish further reduction as a matter of national policy
(25).
Within the lifestyle domain, the established interventions consist
of policies for increasing access to and promoting physical activ-
ity for adults and older children. Emerging interventions in this
domain include strategies to reduce sodium and trans fat consump-
tion (through legislative or market-based actions), the taxation and
counter-marketing of energy-dense (junk) food, improving physic-
al activity in child care, and policies for increasing access to and
promoting the consumption of fruits and vegetables.
In this analysis, we report the results of testing these 6 clusters one
at a time and in combination. When an intervention lever was in-
cluded in a cluster being tested, it was ramped up linearly to a
level of best plausible implementation from 2012 to 2017 and re-
mained in full  effect  thereafter to the end of the simulation in
2040. For some of the interventions (whether established or emer-
ging), the best plausible lever setting was directly measurable (eg,
milligrams of sodium consumed daily, fraction of workplaces al-
lowing smoking), whereas for others it was defined as 100% of an
ideal or best practice as described in the literature or by subject
matter experts.
We report  annual  outcome variables  that  include  preventable
deaths per thousand adults (death rate) that include CVD deaths
and non-CVD deaths attributable to CVD  risk factors, such as
chronic obstructive pulmonary disease, end-stage renal disease,
and various cancers (lung, colorectal, breast, and others); years of
potential life lost per thousand adults;  3 categories of per-adult
cost (direct risk factor management costs, direct acute and exten-
ded care costs, and indirect productivity costs); and the sum of
these per-adult costs (19). Costs were discounted by 3% per year
back to 2012. Cumulative effects are reported as of 2020 and as of
2040, in terms of percentage changes relative to the status quo
base case of no change in intervention levers after 2012.
To test the robustness of results, each of the 6 cluster intervention
scenarios was tested by using probabilistic sensitivity analysis. In
200 Monte Carlo runs of PRISM, 89 different parameters quanti-
fying intervention effect sizes were set to randomly selected val-
ues along assumed uniform probability distributions with estim-
ated mean, minimum, and maximum. These distributional para-
meters were taken from means and confidence intervals reported
in the research literature where available and otherwise from the
estimates of subject matter experts (19).
Results
Cumulative results through 2020
We calculated cumulative results from testing the 6 intervention
clusters (care, air, and lifestyle in both established and emerging
interventions) from 2012 to 2020 (Table 2). Of the 3 policy do-
mains, combining the care interventions led to the greatest reduc-
tion in the death rate (−30.4%; 95% uncertainty range, −33.5% to
−29.3%) and per capita acute and extended care costs (−17.9%;
95% uncertainty range, −21.6% to −15.6%). However, the care in-
terventions also led to a substantial increase in risk factor manage-
ment costs (105.8%; 95% uncertainty range, 94.9% to 117.4%),
which includes the direct costs of office visits, medications, equip-
ment, and ambulatory medical procedures. As a result, the care in-
terventions together did not lead to much, if  any,  reduction in
combined costs (−0.8%; 95% uncertainty range, −4.4% to 1.7%).
The health effects were greater for the established care interven-
tions than for the emerging care interventions, but both made sig-
nificant contributions.
The air  and lifestyle interventions had modest  effects  through
2020. The combined air interventions led to modest reductions in
the death rate (−2.3%; 95% uncertainty range, −2.6% to −1.9%)
and combined costs (−1.9%; 95% uncertainty range, −2.2% to
−1.6%). The health and cost effects were evenly divided between
the established and emerging air interventions. The combined life-
style interventions provided greater reductions in the death rate
(−5.7%; 95% uncertainty range, −7.3% to −4.4%) and combined
costs  (−4.3%;  95% uncertainty  range,  −5.5% to  −3.3%).  The
emerging lifestyle interventions contributed more than the estab-
lished interventions did.
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The combined care, air, and lifestyle interventions resulted in large
reductions  in  the  death  rate  (−32.6%;  95% uncertainty  range,
−34.7%  to −30.6%) and a moderate reduction in combined costs
(−4.5%; 95% uncertainty range, −7.4% to −1.7%). Both estab-
lished and emerging interventions contributed to these reductions,
but the established interventions contributed more than the emer-
ging ones did with respect to health effects, while the emerging in-
terventions contributed more than the established ones did with re-
spect to total costs.
Cumulative results through 2040
We calculated cumulative results from testing the 6 intervention
clusters from 2012 to 2040 (Table 3). The combined care interven-
tions resulted in large reductions in the death rate (−47.7%; 95%
uncertainty range, −51.9% to −45.7%) and a moderate reduction in
combined  costs  (−9.4%;  95%  uncertainty  range,  −14.6%  to
−6.1%). Both established and emerging care interventions contrib-
uted to these improvements, but the established interventions con-
tributed more than the emerging ones did.
The combined air interventions resulted in moderate reductions in
the death rate (−5.6%; 95% uncertainty range, −6.3% to −4.8%)
and combined costs (−4.9%; 95% uncertainty range, −5.6% to
−4.1%). Both established and emerging air interventions contrib-
uted to these improvements, but the established air interventions
contributed more than the emerging ones did.
The combined lifestyle interventions resulted in moderate reduc-
tions in the death rate (−10.8%; 95% uncertainty range, −12.8% to
−8.5%)  and  combined  costs  (−8.6%;  95%  uncertainty  range,
−10.2% to −6.7%). Both established and emerging lifestyle inter-
ventions contributed to these improvements, but the emerging in-
terventions contributed more than the established interventions
did.
The combined care, air, and lifestyle interventions resulted in large
reductions  in  the  death  rate  (−51.3%;  95% uncertainty  range,
−54.1% to −48.7%) and a moderate reduction in combined costs
(−16.5%; 95% uncertainty range, −20.7% to −12.8%). Both estab-
lished and emerging interventions contributed to these improve-
ments, but the established interventions contributed more than the
emerging interventions did with respect to health impacts, where-
as the emerging interventions contributed more than the estab-
lished ones with respect to total costs.
Sensitivity to uncertainties
Results from the probabilistic sensitivity analysis are represented
in the uncertainty ranges (Table 2, Table 3). All of the results de-
scribed above regarding the relative importance of established and
emerging interventions within each of the 3 policy domain areas
and in total are not qualitatively affected by uncertainties.
Discussion
We used PRISM to compare the health and economic effects of
established and emerging public health interventions in care, air,
and lifestyle policy domains. Our testing suggests that established
interventions may still have much to contribute to reducing deaths
through greater use of well-known approaches to preventive and
acute clinical care, whereas emerging interventions have the po-
tential to contribute significantly through certain types of prevent-
ive care and improved nutrition (especially trans fat and sodium
reduction). Considering all areas of intervention (care, air, and
lifestyle) together, emerging interventions have the potential to
improve health significantly, but not by as much as further expan-
sions in established interventions.  The emerging interventions
have  the  potential  to  reduce  costs  significantly,  perhaps  even
somewhat more than the established interventions do, because
they avoid large increases in the costs of risk factor management.
The results reported here may be compared with those of other
modeling studies, such as Kahn et al (16) and Kottke et al (17),
that have assessed the potential impact of multiple CVD interven-
tions individually and in combination. The most directly compar-
able study is Kahn et al, which used the Archimedes microsimula-
tion  model  to  analyze  11 nationally  recommended prevention
activities. These activities were included in our care risk factors,
some of them established (eg, control of existing hypertension,
high cholesterol, and diabetes; pre-CVD aspirin use, smoking ces-
sation, and weight reduction in the obese) and one emerging, con-
trol of prediabetes. The Archimedes model projects that expand-
ing all 11 activities by feasible amounts over the next 30 years
could decrease  myocardial  infarctions  by 36% and strokes  by
20%. The greatest benefits are projected to come from pre-CVD
aspirin use, prediabetes control, weight reduction, diabetes control,
and post-CVD cholesterol  control.  By comparison,  in PRISM,
when all 34 of the care interventions were implemented to their
best  plausible levels,  coronary heart  disease events  (including
myocardial infarctions and episodes of angina pectoris) were re-
duced by 50% and strokes by 56% by the year 2040, relative to the
base case (results available upon request). We have not attempted
a head-to-head comparison of PRISM and Archimedes using equi-
valent assumptions, but even the imperfect comparison above is
helpful. First, PRISM, with its broader array of preventive care in-
terventions, suggests the potential for more reduction in CV events
than Archimedes does, as expected. Second, the Archimedes study
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is consistent with our conclusion that established plus emerging
interventions,  if  they can be implemented successfully,  would
provide significantly greater impact than established interventions
alone.
Our results are subject to several limitations. First, the simplified
compartmental structure of PRISM means that it cannot capture
certain detailed comorbidity effects and distributional effects that
one might see in a microsimulation like Archimedes. The advant-
age of the compartmental approach is that a simulation can be per-
formed in an instant, and thorough sensitivity testing of dozens of
assumptions (as we have done here) thereby becomes practical
(19,20).
Second, although PRISM does model changes in the age distribu-
tion of the population, it does not model changes over time in oth-
er demographic characteristics, such as race/ethnicity, urban/rural
residence, or education and income levels. Nonetheless, the signi-
ficance of such characteristics can be explored by calibrating the
model to represent localities that are demographically different
from the United States overall. Such calibrations have been per-
formed with PRISM and suggest that the general findings here are
unaffected by differences in demographics (15,24).
Third, although the combined costs calculated in PRISM included
indirect  productivity costs  and several  types of  direct  medical
costs, including the direct costs of the model’s 34 care interven-
tions, they do not include the implementation and enforcement
costs of the model’s 16 air and lifestyle interventions. One study
suggests that comprehensive population-level prevention (prevent-
ing smoking, increasing physical activity, and improving nutrition)
could be accomplished for  $10 per  person per  year  (26).  This
amount is 100 times smaller than the nearly $1,000 per person per
year that PRISM calculates would be required in additional pre-
ventive care costs (ie, implementation costs for care levers) for the
model’s 34 care interventions, which still manage to be cost-ef-
fective. Thus, the cost savings from the air and lifestyle interven-
tions are likely to be much larger than their implementation costs,
and our policy findings are likely insensitive to the presence or ab-
sence of these costs in the analysis.
Fourth, the comparisons in this study have used certain outcome
measures for deaths and costs. These are arguably good measures
but others, such as cost per quality-adjusted life year, might yield
different results. Fifth, as with all models, the PRISM estimates of
effect sizes and other parameters are based on data and studies
available at the time of model creation. As research evolves, some
parameter estimates may become outdated. We have regularly up-
dated  PRISM  to  reflect  the  latest  data  and  studies;  the  work
presented here reflects a model update performed in November
2013.
Despite these limitations, PRISM provides public health officials a
unique analytic platform for examining the potential influence of
different kinds of interventions, both established and emerging, for
reducing CVD risks. Our modeling suggests that established inter-
ventions could still contribute much toward reducing deaths and
costs through improvements in preventive and acute care, where-
as emerging interventions have the potential to contribute signific-
antly through other types of preventive care and improved nutri-
tion.
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Tables
Table 1. Interventions, Target Populations, and Risk Factor Management Costs in the Prevention Impacts Simulation Model
(PRISM)
PRISM Intervention Lever
Estimated Target
Population 2010,
millions
Recipient
Population 2010,
if Applicable,
millions
Unit Cost per
Recipient per Year, if
Applicable, 2008 $
Initial Lever
Setting
Best Plausible
Lever Settinga
Care established: 22 intervention levers
Use of quality BP care: non-CVD, post-CVD 78.7b 39.4 440 60 100
Use of quality cholesterol care: non-CVD, post-
CVD
108.6c 35.7 420 55 100
Use of quality diabetes care: non-CVD, post-CVD 26.4d 11.2 1,700 57 100
Use of quality acute and rehabilitative care 3.7e 3.0 26,050 80 100
Use of quality CVD care post-CVD 27.4f 19.2 2,000 70 100
Use of quit counseling and NRT by smokers 51.1g 5.1 619 10 20
Use of weight loss services by obese 75.3h 7.5 650 10 24
Fraction of diagnosed sleep apnea 34.3i 2.9 600 33 100
Fraction of individuals with sleep apnea that
own a CPAP
34.3i 2.9 600 65 100
Fraction of individuals that own a CPAP who use
it
34.3i 2.9 600 40 100
Abbreviations: BP, blood pressure; CVD, cardiovascular disease; post-CVD, already diagnosed with CVD; non-CVD, not yet diagnosed with CVD; NRT, nicotine re-
placement therapy; CPAP, continuous positive airway pressure; PM 2.5, particles smaller than 2.5 µm,—, not applicable.
a Values are percentages unless otherwise indicated.
b Ever told they had high blood pressure or systolic blood pressure (SBP) at or greater than 140 mm Hg or diastolic blood pressure (DBP) at or greater than 90 mm
Hg.
c Ever told they had high cholesterol or low-density lipoprotein (LDL) cholesterol at or greater than 130 mg/dL.
d Ever told they had diabetes or fasting glucose at or greater than 126 mg/dL.
e Fraction of cardiovascular event patients arriving timely to hospital, receiving recommended in-hospital care, and receiving rehabilitative care as appropriate.
f Fraction of post-CVD patients receiving preventive medications or elective revascularization as appropriate.
g Smokers who have smoked within past 6 months and had at least 100 cigarettes in their lifetime.
h Youth obesity defined as greater than 95% percentile by sex and age on Centers for Disease Control and Prevention growth chart from 1970s. Adult obesity
defined as body mass index at or greater than 30 kg/m2.
i Ever told they had obstructive sleep apnea or sleep-disordered breathing.
j Population of individuals with gingivitis or periodontal disease. Periodontal disease is defined as at least 1 site with at or greater than 3 mm clinical attachment
loss and at or greater than 4 mm pocket depth.
k Use every day or every other day, as a fraction of those eligible per the US Preventive Services Task Force (27): men aged 45 to 79, women aged 55 to 79.
l Score at or greater than 6 on Kessler-6 questionnaire for serious psychological distress (28).
m Borderline high blood pressure defined as SBP at or greater than 130 mm Hg or DBP at or greater than 85 mm Hg but not high blood pressure by definition
above.
n Tight control of high blood pressure achieves SBP less than 130 mm Hg and DBP less than 85 mm Hg.
o Borderline high cholesterol defined as LDL cholesterol at or above 110 mg/dL but not high cholesterol by definition above.
p Tight control of high cholesterol achieves LDL cholesterol lower than 100 mg/dL.
q Prediabetes defined as fasting glucose at or greater than 100 mg/dL but not diabetes by definition above.
r Tight control of diabetes achieves HbA1c lower than 5.7%.
s Total population aged 12 or older.
t Total population aged 2 or older.
u Total population aged 6 through 11.
v Total population aged 2 through 5.
(continued on next page)
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(continued)
Table 1. Interventions, Target Populations, and Risk Factor Management Costs in the Prevention Impacts Simulation Model
(PRISM)
PRISM Intervention Lever
Estimated Target
Population 2010,
millions
Recipient
Population 2010,
if Applicable,
millions
Unit Cost per
Recipient per Year, if
Applicable, 2008 $
Initial Lever
Setting
Best Plausible
Lever Settinga
Fraction of individuals that use a CPAP who use
it effectively
34.3i i2.9 600 75 100
Regular dental care to prevent periodontal
disease: non-CVD, post-CVD
129.7j 55.8 300 43 100
Aspirin use by eligible non-CVD population: male,
aged <65 y
39.5k 11.8 14 30 100
Aspirin use by eligible non-CVD population:
female, aged <65 y
18.8k 7.1 14 38 100
Aspirin use by eligible non-CVD population: male,
aged ≥65 y
13.1k 7.9 14 60 100
Aspirin use by eligible non-CVD population:
female, aged ≥65 y
15.6k 8.9 14 57 100
Use of support services by distressed: non-CVD 28l 5.7 2,080 20.6 54
Use of support services by distressed: post-CVD 6.9l 1.6 2,080 23.4 80
Care emerging: 12 intervention levers
Borderline BP care: non-CVD, post-CVD 17.4m 0 220 0 100
Abbreviations: BP, blood pressure; CVD, cardiovascular disease; post-CVD, already diagnosed with CVD; non-CVD, not yet diagnosed with CVD; NRT, nicotine re-
placement therapy; CPAP, continuous positive airway pressure; PM 2.5, particles smaller than 2.5 µm,—, not applicable.
a Values are percentages unless otherwise indicated.
b Ever told they had high blood pressure or systolic blood pressure (SBP) at or greater than 140 mm Hg or diastolic blood pressure (DBP) at or greater than 90 mm
Hg.
c Ever told they had high cholesterol or low-density lipoprotein (LDL) cholesterol at or greater than 130 mg/dL.
d Ever told they had diabetes or fasting glucose at or greater than 126 mg/dL.
e Fraction of cardiovascular event patients arriving timely to hospital, receiving recommended in-hospital care, and receiving rehabilitative care as appropriate.
f Fraction of post-CVD patients receiving preventive medications or elective revascularization as appropriate.
g Smokers who have smoked within past 6 months and had at least 100 cigarettes in their lifetime.
h Youth obesity defined as greater than 95% percentile by sex and age on Centers for Disease Control and Prevention growth chart from 1970s. Adult obesity
defined as body mass index at or greater than 30 kg/m2.
i Ever told they had obstructive sleep apnea or sleep-disordered breathing.
j Population of individuals with gingivitis or periodontal disease. Periodontal disease is defined as at least 1 site with at or greater than 3 mm clinical attachment
loss and at or greater than 4 mm pocket depth.
k Use every day or every other day, as a fraction of those eligible per the US Preventive Services Task Force (27): men aged 45 to 79, women aged 55 to 79.
l Score at or greater than 6 on Kessler-6 questionnaire for serious psychological distress (28).
m Borderline high blood pressure defined as SBP at or greater than 130 mm Hg or DBP at or greater than 85 mm Hg but not high blood pressure by definition
above.
n Tight control of high blood pressure achieves SBP less than 130 mm Hg and DBP less than 85 mm Hg.
o Borderline high cholesterol defined as LDL cholesterol at or above 110 mg/dL but not high cholesterol by definition above.
p Tight control of high cholesterol achieves LDL cholesterol lower than 100 mg/dL.
q Prediabetes defined as fasting glucose at or greater than 100 mg/dL but not diabetes by definition above.
r Tight control of diabetes achieves HbA1c lower than 5.7%.
s Total population aged 12 or older.
t Total population aged 2 or older.
u Total population aged 6 through 11.
v Total population aged 2 through 5.
(continued on next page)
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(continued)
Table 1. Interventions, Target Populations, and Risk Factor Management Costs in the Prevention Impacts Simulation Model
(PRISM)
PRISM Intervention Lever
Estimated Target
Population 2010,
millions
Recipient
Population 2010,
if Applicable,
millions
Unit Cost per
Recipient per Year, if
Applicable, 2008 $
Initial Lever
Setting
Best Plausible
Lever Settinga
Tighter BP care: non-CVD, post-CVD 78.7n 0 88 0 100
Borderline cholesterol care: non-CVD, post-CVD 35.8o 0 378 0 100
Tighter cholesterol care: non-CVD, post-CVD 108.6p 0 126 0 100
Prediabetes care: non-CVD, post-CVD 73.3q 0 850 0 100
Tighter diabetes care: non-CVD, post-CVD 26.4r 0 850 0 100
Air established: 3 intervention levers
Tobacco tax rate 253.4s — — 34 100
Tobacco marketing restriction index 253.4s — — 25 100
Fraction of workplaces allowing smoking 253.4s — — 11 0
Air emerging: 2 intervention levers
Tobacco counter-marketing index 253.4s — — 20 100
Average small particulate air pollution (µg/cubic
meter PM 2.5)
295.4t — — 10.9 7.0
Lifestyle established: 3 intervention levers
Abbreviations: BP, blood pressure; CVD, cardiovascular disease; post-CVD, already diagnosed with CVD; non-CVD, not yet diagnosed with CVD; NRT, nicotine re-
placement therapy; CPAP, continuous positive airway pressure; PM 2.5, particles smaller than 2.5 µm,—, not applicable.
a Values are percentages unless otherwise indicated.
b Ever told they had high blood pressure or systolic blood pressure (SBP) at or greater than 140 mm Hg or diastolic blood pressure (DBP) at or greater than 90 mm
Hg.
c Ever told they had high cholesterol or low-density lipoprotein (LDL) cholesterol at or greater than 130 mg/dL.
d Ever told they had diabetes or fasting glucose at or greater than 126 mg/dL.
e Fraction of cardiovascular event patients arriving timely to hospital, receiving recommended in-hospital care, and receiving rehabilitative care as appropriate.
f Fraction of post-CVD patients receiving preventive medications or elective revascularization as appropriate.
g Smokers who have smoked within past 6 months and had at least 100 cigarettes in their lifetime.
h Youth obesity defined as greater than 95% percentile by sex and age on Centers for Disease Control and Prevention growth chart from 1970s. Adult obesity
defined as body mass index at or greater than 30 kg/m2.
i Ever told they had obstructive sleep apnea or sleep-disordered breathing.
j Population of individuals with gingivitis or periodontal disease. Periodontal disease is defined as at least 1 site with at or greater than 3 mm clinical attachment
loss and at or greater than 4 mm pocket depth.
k Use every day or every other day, as a fraction of those eligible per the US Preventive Services Task Force (27): men aged 45 to 79, women aged 55 to 79.
l Score at or greater than 6 on Kessler-6 questionnaire for serious psychological distress (28).
m Borderline high blood pressure defined as SBP at or greater than 130 mm Hg or DBP at or greater than 85 mm Hg but not high blood pressure by definition
above.
n Tight control of high blood pressure achieves SBP less than 130 mm Hg and DBP less than 85 mm Hg.
o Borderline high cholesterol defined as LDL cholesterol at or above 110 mg/dL but not high cholesterol by definition above.
p Tight control of high cholesterol achieves LDL cholesterol lower than 100 mg/dL.
q Prediabetes defined as fasting glucose at or greater than 100 mg/dL but not diabetes by definition above.
r Tight control of diabetes achieves HbA1c lower than 5.7%.
s Total population aged 12 or older.
t Total population aged 2 or older.
u Total population aged 6 through 11.
v Total population aged 2 through 5.
(continued on next page)
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(continued)
Table 1. Interventions, Target Populations, and Risk Factor Management Costs in the Prevention Impacts Simulation Model
(PRISM)
PRISM Intervention Lever
Estimated Target
Population 2010,
millions
Recipient
Population 2010,
if Applicable,
millions
Unit Cost per
Recipient per Year, if
Applicable, 2008 $
Initial Lever
Setting
Best Plausible
Lever Settinga
Physical activity facilities access index 295.4t — — 61 100
Physical activity promotion index 295.4t — — 1 100
Physical activity in schools index 50.1u — — 27 100
Lifestyle emerging: 8 intervention levers
Average sodium consumption (mg/d):
hypertensives
78.7 — — 3,700 1,850
Average sodium consumption (mg/d):
nonhypertensives
216.8 — — 4,000 2,000
Trans fat fraction of calories 295.4t — — 1.3 0
Junk food tax rate 295.4t — — 1 20
Junk food counter-marketing index 295.4t — — 0 100
Fruit and vegetable access index 295.4t — — 75 100
Fruit and vegetable promotion index 295.4t — — 2.5 100
Physical activity in childcare index 16.8v — — 30 100
Abbreviations: BP, blood pressure; CVD, cardiovascular disease; post-CVD, already diagnosed with CVD; non-CVD, not yet diagnosed with CVD; NRT, nicotine re-
placement therapy; CPAP, continuous positive airway pressure; PM 2.5, particles smaller than 2.5 µm,—, not applicable.
a Values are percentages unless otherwise indicated.
b Ever told they had high blood pressure or systolic blood pressure (SBP) at or greater than 140 mm Hg or diastolic blood pressure (DBP) at or greater than 90 mm
Hg.
c Ever told they had high cholesterol or low-density lipoprotein (LDL) cholesterol at or greater than 130 mg/dL.
d Ever told they had diabetes or fasting glucose at or greater than 126 mg/dL.
e Fraction of cardiovascular event patients arriving timely to hospital, receiving recommended in-hospital care, and receiving rehabilitative care as appropriate.
f Fraction of post-CVD patients receiving preventive medications or elective revascularization as appropriate.
g Smokers who have smoked within past 6 months and had at least 100 cigarettes in their lifetime.
h Youth obesity defined as greater than 95% percentile by sex and age on Centers for Disease Control and Prevention growth chart from 1970s. Adult obesity
defined as body mass index at or greater than 30 kg/m2.
i Ever told they had obstructive sleep apnea or sleep-disordered breathing.
j Population of individuals with gingivitis or periodontal disease. Periodontal disease is defined as at least 1 site with at or greater than 3 mm clinical attachment
loss and at or greater than 4 mm pocket depth.
k Use every day or every other day, as a fraction of those eligible per the US Preventive Services Task Force (27): men aged 45 to 79, women aged 55 to 79.
l Score at or greater than 6 on Kessler-6 questionnaire for serious psychological distress (28).
m Borderline high blood pressure defined as SBP at or greater than 130 mm Hg or DBP at or greater than 85 mm Hg but not high blood pressure by definition
above.
n Tight control of high blood pressure achieves SBP less than 130 mm Hg and DBP less than 85 mm Hg.
o Borderline high cholesterol defined as LDL cholesterol at or above 110 mg/dL but not high cholesterol by definition above.
p Tight control of high cholesterol achieves LDL cholesterol lower than 100 mg/dL.
q Prediabetes defined as fasting glucose at or greater than 100 mg/dL but not diabetes by definition above.
r Tight control of diabetes achieves HbA1c lower than 5.7%.
s Total population aged 12 or older.
t Total population aged 2 or older.
u Total population aged 6 through 11.
v Total population aged 2 through 5.
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Table 2. Grouped Intervention Impacts on Deaths and Costs, 2012 Through 2020
Outcome
% Change from Base Casea (95% Uncertainty Range)b
Base CaseaEstablished Emerging Combined
Care interventionsc
Death rated −23.3 (−26.4 to −20.4) −9.4 (−9.7 to −9.2) −30.4 (−33.5 to −29.3) 5.17
YPLL ratee −22.3 (−25.1 to −19.7) −8.2 (−8.5 to −7.9) −28.4 (−31.1 to −27.5) 66.7
Risk management costsf 66.6 (61.6 to 71.0) 24.4 (19.5 to 30.6) 105.8 (94.9 to 117.4) 612
Acute and extended care
costsg
−11.7 (−15.3 to −8.1) −5.4 (−5.8 to −5.0) −17.9 (−21.6 to −15.6) 636
Productivity costsh −19.7 (−22.4 to −17.2) −7.2 (−7.4 to −7.0) −25.3 (−27.6 to −23.8) 2,217
Combined costsi −3.0 (−5.7 to −0.2) −1.3 (−2.2 to −0.2) −0.8 (−4.4 to 1.7) 3,466
Air interventionsc
Death rated −0.9 (−1.1 to −0.7) −1.84 (−1.8 to −1.2) −2.3 (−2.6 to −1.9) 5.17
YPLL ratee −0.8 (−1.0 to −0.6) −1.2 (−1.5 to −1.0) −2.0 (−2.3 to −1.7) 66.7
Risk management costsf −0.4 (−0.6 to −0.3) −0.1 (−0.2 to −0.1) −0.6 (−0.7 to −0.4) 612
Acute and extended care
costsg
−0.8 (−1.0 to −0.6) −1.4 (−1.7 to −1.1) −2.1 (−2.5 to −1.8) 636
Productivity costsh −1.1 (−1.4 to −0.9) −1.1 (−1.4 to −0.9) −2.2 (−2.5 to −1.9) 2,217
Combined costsi −1.0 (−1.2 to −0.7) −1.0 (−1.2 to −0.8) −1.9 (−2.2 to −1.6) 3,466
Lifestyle interventionsc
Death rated −0.4 (−0.6 to −0.1) −5.5 (−7.0 to −4.0) −5.7 (−7.3 to −4.4) 5.17
YPLL ratee −0.4 (−0.7 to −0.2) −4.7 (−6.1 to −3.5) −5.1 (−6.5 to −3.9) 66.7
Risk management costsf −0.3 (−0.5 to −0.1) −3.5 (−4.2 to −2.7) −3.8 (−4.5 to −2.9) 612
Acute and extended care
costsg
−0.3 (−0.4 to −0.1) −4.2 (−5.7 to −2.8) −4.4 (−6.0 to −3.1) 636
Productivity costsh −0.4 (−0.7 to −0.2) −4.1 (−5.2 to −3.0) −4.4 (−5.6 to −3.4) 2,217
Combined costsi −0.4 (−0.6 to −0.1) −4.0 (−5.1 to −3.1) −4.3 (−5.5 to −3.3) 3,466
Abbreviation: YPLL, years of potential life lost.
a Base case results are cumulative averages from model simulations with only baseline conditions for 2012 through 2020.
b Percentage changes from base case with uncertainty ranges are comparisons of intervention test results against base case for 200 different model Monte Carlo
calibrations defined by random sampling of 89 uncertain effect-size parameters. The number not in parentheses is the median of the 200 comparisons; the 2 num-
bers in parentheses are the 2.5 percentile and 97.5 percentile of the 200 comparisons, respectively.
c Interventions ramp up to full strength over 5 years, from 2012 to 2017.
d Death rate refers to deaths per thousand adults from cardiovascular disease (CVD) or from non-CVD consequences of cardiovascular risk factors.
e YPLL rate refers to years of potential life lost per thousand adults due to these deaths.
f Risk management costs refers to per-adult costs of individual-level clinical and behavioral management of cardiovascular risk factors. Costs are expressed in
2008 dollars per adult and have been discounted back to 2012 using an annual discount rate of 3% per year.
g Acute/extended care costs refers to per-adult costs of acute, rehabilitation, and disability care resulting from cardiovascular events or from other disease attribut-
able to cardiovascular risk factors. Costs are expressed in 2008 dollars per adult and have been discounted back to 2012 using an annual discount rate of 3% per
year.
h Productivity costs refers to per-adult loss of paid or household work contribution due to deaths, disability, and hospitalization from cardiovascular events or attrib-
utable to cardiovascular risk factors. Costs are expressed in 2008 dollars per adult and have been discounted back to 2012 using an annual discount rate of 3%
per year.
i Combined costs refers to the sum of risk management, acute/extended care, and productivity costs. Costs are expressed in 2008 dollars per adult and have been
discounted back to 2012 using an annual discount rate of 3% per year.
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(continued)
Table 2. Grouped Intervention Impacts on Deaths and Costs, 2012 Through 2020
Outcome
% Change from Base Casea (95% Uncertainty Range)b
Base CaseaEstablished Emerging Combined
All 3 intervention areasc
Death rated −23.8 (−26.9 to −20.9) −14.7 (−15.9 to −13.6) −32.6 (−34.7 to −30.6) 5.17
YPLL ratee −22.8 (−25.5 to −20.3) −12.8 (−13.8 to −11.8) −30.4 (−32.2 to −28.7) 66.7
Risk management costsf 65.1 (60.4 to 69.5) 20.0 (14.9 to 26.0) 95.0 (84.8 to 106.7) 612
Acute and extended care
costsg
−12.4 (−15.9 −8.9) −10.1 (−11.7 to −8.6) −21.2 (−24.1 to −18.1) 636
Productivity costsh −20.5 (−23.1 to −18.0) −11.1 (−11.9 to −10.3) −27.2 (−29.0 to −25.4) 2,217
Combined costsi −3.9 (−6.6 to −1.1) −5.8 (−6.7 to −4.1) −4.5 (−7.4 to −1.7) 3,466
Abbreviation: YPLL, years of potential life lost.
a Base case results are cumulative averages from model simulations with only baseline conditions for 2012 through 2020.
b Percentage changes from base case with uncertainty ranges are comparisons of intervention test results against base case for 200 different model Monte Carlo
calibrations defined by random sampling of 89 uncertain effect-size parameters. The number not in parentheses is the median of the 200 comparisons; the 2 num-
bers in parentheses are the 2.5 percentile and 97.5 percentile of the 200 comparisons, respectively.
c Interventions ramp up to full strength over 5 years, from 2012 to 2017.
d Death rate refers to deaths per thousand adults from cardiovascular disease (CVD) or from non-CVD consequences of cardiovascular risk factors.
e YPLL rate refers to years of potential life lost per thousand adults due to these deaths.
f Risk management costs refers to per-adult costs of individual-level clinical and behavioral management of cardiovascular risk factors. Costs are expressed in
2008 dollars per adult and have been discounted back to 2012 using an annual discount rate of 3% per year.
g Acute/extended care costs refers to per-adult costs of acute, rehabilitation, and disability care resulting from cardiovascular events or from other disease attribut-
able to cardiovascular risk factors. Costs are expressed in 2008 dollars per adult and have been discounted back to 2012 using an annual discount rate of 3% per
year.
h Productivity costs refers to per-adult loss of paid or household work contribution due to deaths, disability, and hospitalization from cardiovascular events or attrib-
utable to cardiovascular risk factors. Costs are expressed in 2008 dollars per adult and have been discounted back to 2012 using an annual discount rate of 3%
per year.
i Combined costs refers to the sum of risk management, acute/extended care, and productivity costs. Costs are expressed in 2008 dollars per adult and have been
discounted back to 2012 using an annual discount rate of 3% per year.
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Table 3. Grouped Intervention Impacts on Deaths and Costs 2012 Through 2040
Outcome
% Change from Base Casea (95% Uncertainty Range)b
Base CaseaEstablished Emerging Combined
Care interventionsc
Death rated −35.6 (−40.6 to −31.0) −17.2 (−18.2 to  −16.3) −47.7 (−51.9 to −45.7) 5.74
YPLL ratee −34.8 (−39.3 to −30.5) −15.5 (−16.5 to −14.6) −45.9 (−49.7 to −44.1) 72.1
Risk management costsf 83.3 (76.5 to  89.9) 30.1 (23.8 to 38.2) 128.9 (114.0 to 143.3) 490
Acute and extended care costsg −19.4 (−25.5 to −13.4) −10.8 (−11.6 to −10.1) −31.0 (−33.6 to −27.3) 539
Productivity costsh −31.1 (−35.7 to −26.7) −13.8 (−14.6 to −13.1) −41.2 (−44.6 to −38.8) 1,769
Combined costsi −8.8 (−13.5 to −4.6) −5.5 (−6.9 to −4.0) −9.4 (−14.6 to −6.1) 2,797
Air interventionsc
Death rated −3.5 (−4.2 to −2.8) −2.3 (−2.8 to −1.9) −5.6 (−6.3 to −4.8) 5.74
YPLL ratee −3.2 (−3.8 to −2.5) −2.0 (−2.5 to −1.7) −5.0 (−5.6 to −4.2) 72.1
Risk management costsf −1.7 (−2.0 to −1.2) −0.5 (−0.6 to −0.4) −2.1 (−2.5 to −1.7) 490
Acute and extended care costsg −2.6 (−3.2 to −2.1) −2.3 (−2.9 to −1.9) −4.8 (−5.6 to −4.0) 539
Productivity costsh −3.9 (−4.7 to −3.0) −2.0 (−2.5 to −1.6) −5.7 (−6.4 to −4.8) 1,769
Combined costsi −3.3 (−4.0 to −2.6) −1.8 (−2.2 to −1.5) −4.9 (−5.6 to −4.1) 2,797
Lifestyle interventionsc
Death rated −1.5 (−2.4 to −1.7) −9.7 (−11.8 to −7.6) −10.8 (−12.8 to −8.5) 5.74
YPLL ratee −1.5 (−2.4 to −1.7) −8.6 (−10.4 to −6.7) −9.8 (−11.5 to −7.7) 72.1
Risk management costsf −1.0 (−1.6 to −0.4) −7.1 (−8.1 to −5.8) −7.9 (−8.9 to −6.5) 490
Acute and extended care costsg −0.9 (−1.5 to −0.4) −7.8 (−10.3 to −5.6) −8.5 (−10.9 to −6.2) 539
Productivity costsh −1.4 (−2.1 to −0.6) −7.9 (−9.5 to −6.1) −8.9 (−10.5 to −6.9) 1,769
Combined costsi −1.2 (−1.9 to −0.5) −7.7 (−9.4 to −6.0) −8.6 (−10.2 to −6.7) 2,797
All 3 intervention areasc
Death rated −37.7 (−42.4 to −33.2) −25.0 (−26.7 to −23.1) −51.3 (−54.1 to −48.7) 5.74
Abbreviation: YPLL, years of potential life lost.
a Base case results are cumulative averages from model simulations with only baseline conditions for 2012 through 2040 .
b Percentage changes from base case with uncertainty ranges are comparisons of intervention test results against base case for 200 different model Monte Carlo
calibrations defined by random sampling of 89 uncertain effect-size parameters. The number not in parentheses is the median of the 200 comparisons; the 2 num-
bers in parentheses are the 2.5 percentile and 97.5 percentile of the 200 comparisons, respectively.
c Interventions ramp up to full strength over 5 years, from 2012 to 2017.
d Death rate refers to deaths per thousand adults from cardiovascular disease (CVD) or from non-CVD consequences of cardiovascular risk factors.
e YPLL rate refers to years of potential life lost per thousand adults due to these deaths.
f Risk management costs refers to per-adult costs of individual-level clinical and behavioral management of cardiovascular risk factors. Costs are expressed in
2008 dollars per adult and have been discounted back to 2012 using an annual discount rate of 3% per year.
g Acute/extended care costs refers to per-adult costs of acute, rehabilitation, and disability care resulting from cardiovascular events or from other disease attribut-
able to cardiovascular risk factors. Costs are expressed in 2008 dollars per adult and have been discounted back to 2012 using an annual discount rate of 3% per
year.
h Productivity costs refers to per-adult loss of paid or household work contribution due to deaths, disability, and hospitalization from cardiovascular events or attrib-
utable to cardiovascular risk factors. Costs are expressed in 2008 dollars per adult and have been discounted back to 2012 using an annual discount rate of 3%
per year.
i Combined costs refers to the sum of risk management, acute/extended care, and productivity costs. Costs are expressed in 2008 dollars per adult and have been
discounted back to 2012 using an annual discount rate of 3% per year.
(continued on next page)
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Table 3. Grouped Intervention Impacts on Deaths and Costs 2012 Through 2040
Outcome
% Change from Base Casea (95% Uncertainty Range)b
Base CaseaEstablished Emerging Combined
YPLL ratee −36.8 (−41.1 to −32.6) −22.4 (−23.9 to −20.7) −49.2 (−51.7 to −47.0) 72.1
Risk management costsf 78.6 (71.6 to 85.7) 21.1 (14.5 to 28.6) 107.0 (94.0 to 122.7) 490
Acute and extended care costsg −21.6 (−27.5 to −15.8) −18.7 (−21.1 to −16.1) −36.6 (−41.2 to −31.9) 539
Productivity costsh −33.5 (−37.6 to −29.2) −20.2 (−21.5 to −18.7) −44.6 (−47.1 to −42.2) 1,769
Combined costsi −11.5 (−16.1 to −7.3) −12.7 (−14.4 to −10.6) −16.5 (−20.7 to −12.8) 2,797
Abbreviation: YPLL, years of potential life lost.
a Base case results are cumulative averages from model simulations with only baseline conditions for 2012 through 2040 .
b Percentage changes from base case with uncertainty ranges are comparisons of intervention test results against base case for 200 different model Monte Carlo
calibrations defined by random sampling of 89 uncertain effect-size parameters. The number not in parentheses is the median of the 200 comparisons; the 2 num-
bers in parentheses are the 2.5 percentile and 97.5 percentile of the 200 comparisons, respectively.
c Interventions ramp up to full strength over 5 years, from 2012 to 2017.
d Death rate refers to deaths per thousand adults from cardiovascular disease (CVD) or from non-CVD consequences of cardiovascular risk factors.
e YPLL rate refers to years of potential life lost per thousand adults due to these deaths.
f Risk management costs refers to per-adult costs of individual-level clinical and behavioral management of cardiovascular risk factors. Costs are expressed in
2008 dollars per adult and have been discounted back to 2012 using an annual discount rate of 3% per year.
g Acute/extended care costs refers to per-adult costs of acute, rehabilitation, and disability care resulting from cardiovascular events or from other disease attribut-
able to cardiovascular risk factors. Costs are expressed in 2008 dollars per adult and have been discounted back to 2012 using an annual discount rate of 3% per
year.
h Productivity costs refers to per-adult loss of paid or household work contribution due to deaths, disability, and hospitalization from cardiovascular events or attrib-
utable to cardiovascular risk factors. Costs are expressed in 2008 dollars per adult and have been discounted back to 2012 using an annual discount rate of 3%
per year.
i Combined costs refers to the sum of risk management, acute/extended care, and productivity costs. Costs are expressed in 2008 dollars per adult and have been
discounted back to 2012 using an annual discount rate of 3% per year.
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